A carregar...

PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives

More than simply a promising management option, PARP inhibitors can be regarded as a milestone in the development of personalised treatment of recurrent ovarian carcinoma. Their mechanism of action, known as “synthetic lethality”, is dependent on functional differences of the DNA repair mechanisms o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Geburtshilfe Frauenheilkd
Main Authors: Sehouli, J., Braicu, E. I., Chekerov, R.
Formato: Artigo
Idioma:Inglês
Publicado em: Georg Thieme Verlag KG 2016
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4771499/
https://ncbi.nlm.nih.gov/pubmed/26941449
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1055/s-0035-1558185
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!